Gilead Sciences, Inc. Looks To Erase Bristol-Myers Squibb Company's Early Hep C Lead

Excitement is growing ahead of the Food and Drug Administration's decision on Gilead Sciences (NASDAQ: GILD ) next generation hepatitis C treatment. Most expect that the regulator will give the Sovaldi and ledipasvir combination drug the green light when it makes its decision on October 10, but Gilead isn't sitting back on its heels waiting. The company announced this week that it's also submitted the Sovaldi and ledipasvir one-drug therapy for approval in Japan, one of the globe's biggest markets for hepatitis C treatment.

Hey, check out all the research scientist jobs. Post your resume today!